The FDA has approved a new blood test that can help diagnose Alzheimer's disease, offering a non-invasive alternative to current methods which often require invasive spinal taps. This development is significant as it could streamline the diagnostic process, making early detection more accessible and potentially leading to better patient management and treatment outcomes.